Evidence for pleiotropic effects of statins in clinical trials

Ping Yen Liu, Chao Yung Wang, James K. Liao

研究成果: Article同行評審

摘要

Lipid-lowering agents, such as 3-hydroxy-3-methylglutaryl coenzyme A(HMG CoA) Teductase inhibitors, also known as statins, have been shown to reduce cardiovascular events. However, evidence from recent clinical trials suggests that the beneficial effects of statins may be derived from both lipid lowering and non-lipid lowering, or "pleiotropic" effects. Animal studies suggest that some of these pleiotropic effects of statins are mediated by inhibition of Rho kinase (ROCK). ROCK has been shown important in regulation of vascular tone, cell proliferation, inflammation and oxidative stress. In the cardiovascular system RhoA/ROCK pathway has also been implicated in angiogenesis, atherosclerosis, cerebral and coronary vasospasm, cerebral ischemia, hypertension, myocardial hypertrophy, and neointima formation after vascular injury. Indeed, in clinical studies, elevated ROCK activity is associated with cardiovascular risks and inhibition of ROCK leads to improved endothelial function. Therefore, modulation of the RhoA/ROCK pathway by statins may provide additional benefits beyond their lipid lowering effects, especially among high-risk cardiovascular patients.

原文English
頁(從 - 到)116-121
頁數6
期刊Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry
8
發行號2
DOIs
出版狀態Published - 2008 6月

All Science Journal Classification (ASJC) codes

  • 內分泌學、糖尿病和代謝
  • 免疫學和過敏
  • 藥理

指紋

深入研究「Evidence for pleiotropic effects of statins in clinical trials」主題。共同形成了獨特的指紋。

引用此